Dott. Roberto Pistolesi
Dragotti & Associati S.R.L.
Via Nino Bixio, 7
20129 Milano
Italy
Roberto has background in organic chemistry. He frequently advises clients on patent strategies and provides infringement and validity opinions and has an extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 100 cases before the Opposition Divisions or the Boards of Appeal.
He also has a wide expertise in multi-national patent litigations; in particular, he has been involved as party expert in patent litigations concerning the following active principles: alendronic acid (Fosamax), alirocumab (Praulent), atorvastatine (Torvast), cefaclor, citalopram (Celexa), docetaxel (Taxotere), enoxaparine (Lovenox), esomeprazole (Nexium), everolimus (Linevero), phosphatidylserine, gabapentin (Neurontin), irbesartan+HCTZ (Co-Aprovel), latanoprost (Xalatan), olanzapine (Zyprexa), omega-3, omeprazole (Omeprazen), montelukast (Singulair), natalizumab (Tysabri), quetiapine (Seroquel), ramipril, repaglinide (Novonorm), rupatadine, salmeterol + fluticasone, sildenafil (Viagra), tadalafil (Cialis) and terbinafine (Lamisil).
Roberto has background in organic chemistry. He frequently advises clients on patent strategies and provides infringement and validity opinions and has an extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 100 cases before the Opposition Divisions or the Boards of Appeal.
He also has a wide expertise in multi-national patent litigations; in particular, he has been involved as party expert in patent litigations concerning the following active principles: alendronic acid (Fosamax), alirocumab (Praulent), atorvastatine (Torvast), cefaclor, citalopram (Celexa), docetaxel (Taxotere), enoxaparine (Lovenox), esomeprazole (Nexium), everolimus (Linevero), phosphatidylserine, gabapentin (Neurontin), irbesartan+HCTZ (Co-Aprovel), latanoprost (Xalatan), olanzapine (Zyprexa), omega-3, omeprazole (Omeprazen), montelukast (Singulair), natalizumab (Tysabri), quetiapine (Seroquel), ramipril, repaglinide (Novonorm), rupatadine, salmeterol + fluticasone, sildenafil (Viagra), tadalafil (Cialis) and terbinafine (Lamisil).
Roberto has been a technical expert of the Court of Milan since 2002 and of the Court of Venice since 2015, where he assists Judges in patent infringement and/or validity cases; in January 2023 he was appointed as technical expert of the Board of Appeal of the Court of Milan.
He was adjunct Professor at the “Universita’ degli Studi” of Milan from 2011 to 2015, where he taught chemical patent practice to the students of Chemical Science, Industrial Chemistry and Biotechnology.
He has been President of FICPI since September 2022. He was Secretary General of FICPI from April 2015 to September 2022, and chairman of FICPI’s study and work commission dealing with inventions in the pharma and biotech area from April 2012 to April 2015.
He frequently lectures on intellectual property both in Italy and abroad. He has published several articles on “Il Sole-24 Ore”, “Pharmachem” and “Il Diritto Industriale”; he is co-author of the Italian and European sections of “Biotechnology and Pharmaceutical Patents – Law and Practice”, Wolters Kluwer, 2008 and 2009 editions.
Education
- Degree in Bio-Organic Chemistry (Università degli Studi di Milano)
- CEIPI diploma on patent litigations in Europe
Bar admissions
- Since June 1998: Italian patent agent
- Since September 1999: Italian trademark agent
- Since March 2000: European patent attorney
- Since June 2000: Community trademark attorney
- Since March 2023: Patent litigator admitted before the UPC
Professional Experience
Partner and CEO of Dragotti & Associati.
Experience & Qualifications
- Biochemistry and pharmacology
- Biotechnology; plant technology
- Chemistry
- Food technology
- Industrial chemistry and chemical engineering
- IP counselling
- Patent drafting
- Patent litigation
- Patent oppositions
- Patent prosecution
Roles in FICPI
-
CET Executive
The President of the CET is elected by the ExCo.
The CET further includes at least one vice president, a Reporter General and an Assistant Reporter General, who, together with the president are responsible for managing the CET.
The Chair and members of the sub-groups are chosen by the CET, after consulting the Bureau and the Council for opinions, from lists of candidates including members of the national associations or national sections and, in suitable cases, individual members. By proposing members of the groups, the member national sections and associations are able to influence FICPI policy.
Members of the Bureau and the presidents of PMC and TEC are ex officio members of the CET.
- Ex Officio Member
Communications Committee
- Ex Officio Member
Bureau
- President
Advisory Council
- Bureau
Nominating Committee
- Member
Strategic Planning Committee
- Coordinator
Training & Education Committee
- Ex Officio Member
Webinar Committee
- Member
- Italian
- English
- French